Summary:
A phase ii multi-center, randomized, doubleblind, 24-week, parallel group, placebo-controlled study to investigate the efficacy and safety of balovaptan (ro5285119) in children and adolescents age 5-12 with autism spectrum disorder (asd).
Qualified Participants Must:
• 5-12 years old
•
Be diagnosed with autism
•
Have an IQ score of 70 or above
•
Have some level of verbal fluency
Qualified Participants May Receive:
- Compensation
- Comprehensive autism evaluation by a physician
- Intelligence testing
- Labs
- Medications at no cost
- Potential inclusion in year long extension study